本帖最后由 老马 于 2013-3-13 13:43 编辑 ! c% X. V5 o% h. z
/ k! j. z% j& a) E. b/ W- c健择（吉西他滨）+顺铂+阿瓦斯汀9 e( _6 d8 S$ b. [8 p( n! y+ H4 b
Gemzar +Cisplatin + Avastin
$ _" q) g$ D6 M; l$ Q" Ahttp://annonc.oxfordjournals.org/content/21/9/1804.full
( K" \ f' ? |+ F2 Z" J. COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 Q' E" J2 `1 p# B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. & |2 |0 t% [" X, n
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ e7 C6 `8 Z# m: V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 851)
7 u; \' \& \8 v6 q8 N
华为网盘附件：& l5 h6 ^2 L3 @& c
【华为网盘】ava.JPG3 e9 ~1 T/ N: s, e" T* f. K
|
显身卡
